Formulations containing sphinganine

Patent metadata

Field	Value
Publication number	US-9913789-B2
Application number	US-201414908195-A
Country	US
Kind code	B2
Filing date	Jul 1, 2014
Priority date	Jul 29, 2013
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

The present invention relates to formulations comprising
A) sphinganine and B) at least one active ingredient selected from the group
creatine, creatinine, caffeine, carnitine, biotin, arjunolic acid, xymenynic acid, minoxidil, arginine and derivatives thereof.

First claim

The invention claimed is:

1. A formulation, comprising:
component A): sphinganine in an amount of at least 0.05% by weight; and
component B): one or more active ingredients selected from the group consisting of: creatine; creatinine; caffeine; carnitine; biotin; arjunolic acid; xymenynic acid; minoxidil; arginine; and derivatives thereof, wherein said derivatives are acids, esters, amides, alcohols, alcoholates, aldehydes, amines, salts, hydrates, glucosides, isomers or enantiomers of said active ingredients;
and wherein sphinganine and said active ingredients are present in amounts such that said formulation is more effective at stimulating the proliferation of follicular dermal papilla cells in vitro, or hair growth in vivo, than the stimulation that can be obtained when either said sphinganine or said active ingredients are present in the absence of the other.

2. The formulation of claim 1 , wherein component B comprises one or more derivatives selected from the group consisting of: creatine hydrates; disodium phosphocreatine; caffeine benzide; caffeine carboxylic acid; caffeine hydrates; carnitine HCl; acetyl carnitine; acetyl carnitine HCl; carnitine fumarate; carnitine hydroxycitrate; carnitine linoleate; carnitine pyroglutamate; carnitine tartrate; palmitoyl carnitine; D/L-carnitine; D/L-carnitine HCl; hexadecanoyl carnitine; levo carnitine; allantoin biotin; biotinoyl hexapeptide-2 amide; biotinoyl pentapeptide-4; biotinoyl tripeptide-1; biotinoyl tripeptide-35; ethyl biotinate; monoethanolamine biotinate biotin ethyl ester; biotinum; acetyl arginine; and arginine HCl.

3. The formulation of claim 1 , wherein component A is present at a concentration of 0.05% by weight to 5.0% by weight.

4. The formulation of claim 1 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

5. The formulation of claim 2 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

6. The formulation of claim 3 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

7. The formulation of claim 2 , wherein component A is present at a concentration of 0.05% by weight to 1.0% by weight.

8. The formulation of claim 7 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

9. The formulation of claim 1 , wherein the weight ratio of component A to component B is 1:1 to 1:2000.

10. The formulation of claim 9 , wherein component B comprises one or more derivatives selected from the group consisting of: creatine hydrates; disodium phosphocreatine; caffeine benzide; caffeine carboxylic acid; caffeine hydrates; carnitine HCl; acetyl carnitine; acetyl carnitine HCl; carnitine fumarate; carnitine hydroxycitrate; carnitine linoleate; carnitine pyroglutamate; carnitine tartrate; palmitoyl carnitine; D/L-carnitine; D/L-carnitine HCl; hexadecanoyl carnitine; levo carnitine; allantoin biotin; biotinoyl hexapeptide-2 amide; biotinoyl pentapeptide-4; biotinoyl tripeptide-1; biotinoyl tripeptide-35; ethyl biotinate; monoethanolamine biotinate biotin ethyl ester; biotinum; acetyl arginine; and arginine HCl.

11. The formulation of claim 9 , wherein component A is present at a concentration of 0.05% by weight to 5.0% by weight.

12. The formulation of claim 9 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

13. The formulation of claim 10 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

14. The formulation of claim 11 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

15. The formulation of claim 10 , wherein component A is present at a concentration of 0.05% by weight to 1.0% by weight.

16. The formulation of claim 15 , wherein component B is present at a concentration of 0.01% by weight to 20.0% by weight.

Assignees

• Evonik Degussa Gmbh

Inventors

• Köhler Tim
• Farwick Mike
• Mentel Matthias
• Lersch Peter

Classifications

• A61P17/14

  for baldness or alopecia · CPC title

• A61K31/522

  having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir · CPC title

• A61K31/4188

  condensed with other heterocyclic ring systems, e.g. biotin, sorbinil · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K8/44

  Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof · CPC title